Voluntary licensing agreements can be a powerful tool to facilitate global access to essential medicines—but without careful attention to their features, their impact on access in LMICs will be too little, too late.

Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...

On December 13th 2022, CGD Senior Fellow Prashant Yadav appeared before the House Foreign Affairs Subcommittee on International Development, International Organizations, and Global Corporate Social Impact at a hearing titled “Modernizing International Development Assistance: Opportunities and Challe...

The unprecedented turnout at rallies across Pakistan protesting corruption and poor job prospects underscores the frustration among the rapidly growing middle class with governance failures. Pakistan’s economic growth exceeded India’s for over four decades after its independence in 1947, but since t...

There is a very real possibility that the UK ceases to be a significant presence in international development over the next couple of years; indeed, this is the most likely outcome at present. In this note, we set out the challenges facing Mitchell, and how each of our recommendations can be achieve...

Drug-resistant infections kill an estimated 23,210 Japanese citizens every year. The government of Japan is considering a program that would provide minimum guaranteed revenue to the successful developers of new antibiotics. We present the results of a modelling exercise to estimate the likely retur...

Drug-resistant infections kill an estimated 7,600 UK citizens every year. Without investment for new antimicrobials, deaths from drug-resistant infections could increase dramatically in the coming decade. We present the results of a modelling exercise to estimate the likely ROI from an expanded prog...